Skip to main content

Table 3 Immunology response of patients \( \left(\overline{x}\pm \mathrm{s}\right) \)

From: Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Group

CD3+(%)

CD3+CD4+(%)

CD3+CD8+(%)

CD4+/CD8+

CD3−CD56+(%)

IL-2 (ng/L)

IFN-r (pg/mL)

Treatment group

       

 Pre-treatment

62.16 ± 13.62

33.64 ± 10.05

25.86 ± 10.30

1.55 ± 0.88

17.83 ± 9.04

330.42 ± 79.25

575.85 ± 179.85

 Post-treatment

66.34 ± 13.65

34.63 ± 13.28

29.73 ± 11.14

1.45 ± 0.97

17.31 ± 9.50

330.94 ± 66.12

567.12 ± 151.64

 P value

0.3

0.716

0.119

0.684

0.806

0.979

0.831

Control group

       

 Pre-treatment

68.70 ± 15.48

39.48 ± 12.76

27.30 ± 8.79

1.57 ± 0.67

10.25 ± 6.12

358.37 ± 49.00

491.19 ± 60.00

 Post-treatment

70.43 ± 19.67

33.6471 ± 18.02

33.65 ± 17.19

1.27 ± 0.96

8.52 ± 6.52

376.09 ± 44.44

507.32 ± 59.87

 P value

0.705

0.051

0.077

0.08

0.378

0.186

0.481